GSK may be target of Anonymous hackers; Bristol says anti-trust wait over for Amylin deal; Daiichi Sankyo says its loves social IT tool;

 @FiercePharma:  Patent cliff news that's good for the NHS, not so much for pharma: U.K. scripts up, costs down--Reuters. More | Follow @FiercePharma

> The IT security firm Radware says GlaxoSmithKline ($GSK) is among targets that the computer hacking group Anonymous intends to hit during the Olympics.  Story

> As Johnson & Johnson ($JNJ) is gets plant problems under control and plans to relaunch tin coming months the consumer products that have been out of stock, there is evidence consumers have moved on to other, often cheaper, products. Story

> Bristol-Myers Squibb ($BMY) says the waiting period under the Hart-Scott-Rodino Antitrust provisions has expired paving its way to complete its $7 billion acquisition of Amylin. Release

> Pharmacy benefit manager Express Scripts has tapped drug wholesaler AmerisourceBergen over Cardinal Health to be its distribution partner in a three-year supply deal, worth $18.5 billion annually. Story

> Vertex Pharmaceuticals ($VRTX) had its shares downgraded by a variety of analysts including Piper Jaffray, UBS and Bank of America, while analysts at Needham & Company reiterated a "buy" rating, on the company which in May had to acknowledge it had mistakenly announced flawed clinical results on how its cystic fibrosis drug Kalydeco worked with another therapy.  Story

Medical Device News

@FierceMedDev: Cool science news: researchers have developed a mechanosensor that could be used for biomed sensing and artifical skin. More | Follow @FierceMedDev

 @MarkHFierce: The use of transcatheter aortic valve implants may be based on shaky evidence. More | Follow @MarkHFierce

 @DamianFierce: After closing its $241 Medtox acquisition, LabCorp denies it's a buyout target. Article | Follow @DamianFierce

> New flexible sensor tech mulled as basis for artificial skin. News

> Olympus slapped with DOJ inquiries, Terumo shareholder lawsuit. Article

> Affymetrix posts boosts in revenue, income after acquisition. Story

> ADHD-treating video game charts novel approval path. More

Biotech News

 @FierceBiotech: Medidata lands record $100M deal with a Big Pharma. More | Follow @FierceBiotech

 @JohnCFierce: Can a new Pfizer find success in its long-struggling R&D division? More | Follow @JohnCFierce

 @RyanMFierce: Call me skeptical. Moncef Slaoui wants to jump-start pharma innovation, use bioelectronics to treat disease. More | Follow @RyanMFierce

> The top 15 biotech venture investments in H1 2012. Report

> Adimab, Mersana strike deal to make antibody-drug combos for pharma. News

> Buzz: Avalon Ventures passes the hat on $200M biotech fund. Article

> Can a new Pfizer find success in its long-struggling R&D division? More

> Pfizer faces delay on tofacitinib as new data adds blockbuster luster. Story

Drug Delivery News

> $27M funding will help advance Mersana's ADC pipeline. Story

> InSite Vision starts Phase III for post-surgery eye pain treatment. Article

> Israeli government invests $11M in nanodelivery. News

Biomarkers News 

> GSK to leave phenomenal Olympic legacy for biomarker research. News

> LifeCodexx gets go ahead for Down syndrome test in Switzerland. Story

> Genetic mutation behind rare childhood paralysis. Article

> Gene fusion signposts aggressive brain cancer. More

And Finally... The U.K. division of Japanese pharma company Daiichi Sankyo says the internal social networking tool Chatter has not only revolutionized employee communication but also its relationship with customers. Story